Crescent Biopharma Inc [CBIO] stock is trading at $13.51, up 8.08%. An important factor to consider is whether the stock is rising or falling in short-term value. The CBIO shares have gain 25.21% over the last week, with a monthly amount glided 4.57%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Crescent Biopharma Inc [NASDAQ: CBIO] stock has seen the most recent analyst activity on August 25, 2025, when Jefferies initiated its Buy rating and assigned the stock a price target of $26. Previously, H.C. Wainwright started tracking the stock with Buy rating on August 11, 2025, and set its price target to $25. On July 14, 2025, Wedbush initiated with a Outperform rating and assigned a price target of $27 on the stock. Stifel started tracking the stock assigning a Buy rating and suggested a price target of $28 on June 25, 2025. Cantor Fitzgerald initiated its recommendation with a Overweight. TD Cowen downgraded its rating to Hold for this stock on July 26, 2024. In a note dated December 22, 2023, CapitalOne initiated an Overweight rating and provided a target price of $12 on this stock.
Crescent Biopharma Inc [CBIO] stock has fluctuated between $9.81 and $37.00 over the past year. Currently, Wall Street analysts expect the stock to reach $29 within the next 12 months. Crescent Biopharma Inc [NASDAQ: CBIO] shares were valued at $13.51 at the most recent close of the market. An investor can expect a potential return of 114.66% based on the average CBIO price forecast.
Analyzing the CBIO fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.4, Equity is -0.85 and Total Capital is -0.48. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Crescent Biopharma Inc’s Current Ratio is 6.63. On the other hand, the Quick Ratio is 6.63, and the Cash Ratio is 6.56.
Transactions by insiders
Recent insider trading involved Fairmount Funds Management LLC, Director, that happened on Dec 04 ’25 when 1.36 million shares were purchased.
